Krystal Biotech, Inc.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Krish S. Krishnan M.B.A., M.S.

Employees

295

Headquarters

Pittsburgh, PA, United States

Website

www.krystalbio.com